Presently, we have strong evidence that DMDs (SGLT2i and GLP1 RA) are prognosis changing [9–17] in the sense that they can reduce diabetes related complications far beyond their glucose lowering effect. The gene discussed is GLP1R; the disease is diabetes mellitus.